Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
561-580 of 1,782 trials

Atrial Fibrillation: Apixaban vs. Warfarin in Dialysis Patients

We are comparing the safety and effectiveness of apixaban and warfarin for patients with atrial fibrillation on peritoneal dialysis. The study focuses on bleeding risks and the prevention of strokes and other serious health events.

Chronic Ambulatory Peritoneal DialysisConfirmation phase (III)No PlaceboStandard MedicinesCardiologyNephrology

Asciminib Roll-over Study for Leukemia Patients

We are examining the long-term safety of asciminib in patients with certain types of leukemia who have completed a previous study. This trial aims to see if continued treatment is beneficial for these patients.

Chronic Myeloid Leukaemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Extracranial Malignant Germ Cell Tumors: Carboplatin vs. Cisplatin

We are comparing the effectiveness and side effects of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumors. This study aims to improve treatment options and patient quality of life.

Malignant Extracranial Germ Cell Tumours>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Systemic Lupus Erythematosus: CABA-201 T Cell Therapy

We are studying a new T cell therapy for people with active systemic lupus erythematosus to see if it is safe and effective. This research aims to understand how it affects disease activity and overall health.

Systemic Lupus Erythematosus>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyRheumatology

Vertebral Osteomyelitis: Early Oral Antibiotics Study

We are investigating if switching to oral antibiotics after one week is as effective as continuing intravenous treatment for pyogenic vertebral osteomyelitis. This study will also assess safety, hospital stays, and quality of life for patients.

Pyogenic Vertebral Osteomyelitis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesOrthopedics and TraumatologyRheumatology

Multiple Sclerosis: Ocrelizumab Access Study

We are exploring how multiple sclerosis impacts patients physically while ensuring they can continue receiving ocrelizumab treatment. This study also looks at the safety and tolerability of the medication.

Multiple Sclerosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineNeurology

Membranous Nephropathy: Dapagliflozin Treatment Study

We are investigating how dapagliflozin affects immune activity and kidney function in patients with Membranous Nephropathy. This study may help us understand its potential benefits for managing this condition.

Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineNephrology

Myotonic Dystrophy Type I: Metformin Study

We are investigating whether metformin can improve muscle and overall function in patients with Myotonic Dystrophy Type I. The study will also assess the safety of metformin and its effects on quality of life.

Myotonic Dystrophy Type 1 (DM1)>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Solid Tumors: Selpercatinib Access Program

We are providing access to selpercatinib for adults with locally advanced or metastatic solid tumors that have specific genetic changes. This program aims to help patients who may benefit from this targeted treatment.

Various Types of Cancer>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Hepatocellular Carcinoma: Durvalumab and Bevacizumab Study

We are studying whether the combination of durvalumab and bevacizumab can help prevent cancer recurrence in patients with hepatocellular carcinoma after surgery or ablation. This trial compares these treatments to a placebo to assess their effectiveness.

Early Stage Liver Cancer>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteHepatologyOncology

Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

Chronic Lymphocytic Leukemia6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Rheumatoid Arthritis: MethMax Trial

We are studying how well methotrexate works for people with active rheumatoid arthritis. The goal is to see if it helps more patients reach remission or low disease activity compared to current treatments.

Rheumatoid Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineRheumatology

Axial Spondyloarthritis: Risankizumab Treatment

We are studying the effects of a new treatment for patients with very early axial spondyloarthritis. The goal is to see if it can reduce disease activity and improve overall function.

Axial Spondyloarthritis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Hemophilia A: Long-Term Follow-Up of BMN 270

We are investigating the long-term safety and effects of a gene therapy for severe hemophilia A in individuals who participated in a previous study. This includes looking at their quality of life and the need for additional treatments.

Hemophilia A>2 yearsMonitoring phase (IV)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematology

Progesterone for Preventing Preterm Birth in Women with Placenta Previa

We are studying whether progesterone can help reduce the risk of preterm birth in women diagnosed with placenta previa. This trial will look at various outcomes, including the timing of birth and any side effects for mothers and babies.

Placenta Previa3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsPediatrics

Cirrhosis and Ascites: Fecal Microbiota Transfer Capsules

We are testing the safety of FMT capsules for patients with cirrhosis and ascites to see if they may help reduce immune activation. This study will also look for signs of effectiveness compared to a placebo.

Cirrhosis of the Liver1-2 yearsEfficacy phase (II)Standard MedicinesCost ReimbursementGastroenterologyHepatology

Childhood Epilepsy: Perampanel Treatment Study

We are studying the effects of perampanel, given with other epilepsy medications, in children under 18. The goal is to see if it helps reduce seizures and improve overall health and development.

Childhood EpilepsyEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurologyPediatrics

Pulmonary Embolism: Surveillance vs. Anticoagulation

We are studying whether monitoring without blood thinners is as safe and effective as using them for low-risk patients with isolated subsegmental pulmonary embolism. This trial will also assess side effects and quality of life for participants.

Isolated Subsegmental Pulmonary Embolism3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesPartially RemoteCardiologyPulmonology

Cardiac Anesthesia: Eleveld Model for Propofol and Remifentanil

We are studying how well a new model predicts drug levels of propofol and remifentanil in patients undergoing heart surgery. This research may help improve anesthesia safety and effectiveness during cardiac procedures.

Heart Disorders1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology

Satralizumab for Pediatric Neuromyelitis Optica Spectrum Disorder

We are studying how well satralizumab works and its safety in children aged 2-11 with AQP4 antibody positive neuromyelitis optica spectrum disorder. This research aims to improve treatment options for these young patients.

Neuromyelitis Optica Spectrum Disorder (NMOSD)6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPediatrics